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Introduction
Patients with chronic obstructive pulmonary disease (COPD) have high rates of
cardiovascular comorbidities, including hypertension, ischemic heart disease, and heart failure.1
These comorbidities further complicate management of COPD patients. Cardiovascular
complications are especially difficult to manage during acute exacerbations of chronic
obstructive pulmonary disease (AECOPD). Multiple factors are contributory, including
hypoxemia, tachycardia, increased inflammation, and arterial stiffness.2 Cardioselective betablockers have been proven to be safe and effective in managing cardiovascular conditions such
as heart failure and arrhythmias and are recommended for acutely decompensated heart failure
and myocardial infarction in the setting of AECOPD. Benefits include reducing all-cause
mortality and the risk of COPD exacerbations.1 However, beta-blockers continue to be
underused in COPD patients due to lingering concerns about bronchospasm leading to
exacerbation of COPD symptoms requiring hospitalization.3 Whether the use of beta-blockers
for cardiovascular disease in patients with COPD would decrease pulmonary function or increase
frequency of exacerbations, hospitalizations, and mortality will be examined.

Discussion
Findings
In retrospective and observational studies, the use of cardioselective beta-blockers
decreases mortality and increases survival rates, especially in the acute setting. In a study by
Wang et al. done in Taiwan, patients with newly diagnosed acute myocardial infarction (AMI)
and concurrent COPD (23,116 participants), the treatment of the AMI was categorized as betablockers, both selective (2,859) and non-selective (4,750), and those treated without beta-
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blockers (15,507). Patients treated with beta-blockers had a higher prevalence of co-morbidities
such as hypertension, diabetes, and end-stage renal disease. Patients with cardio-selective betablockers were also more like to be treated with percutaneous coronary intervention (PCI),
indicating more severe cardiovascular disease. However, patients treated initially with
cardioselective beta-blockers had a statistically significant reduced mortality risk (HR 0.93) and
increased both short-term and long-term survival rates compared with patients not treated with
beta-blockers.4 In the acute setting, the benefits seemed to outweigh the risks for treating COPD
patients with cardioselective beta-blockers during an AMI. Although mortality was decreased,
this study did not look at the long-term morbidity or adverse effects from the use of betablockers after discharge from the hospital. Due to the limited amount of information from
coding data from insurance companies, there was no way to track if beta-blockers were
continued as long-term treatment for the patient. Similarly, in Austrian patients with COPD who
were treated for coronary artery disease (CAD) with beta-blockers in 2006 (n=12,628), Rezaei et
al. found that 6.9% of patients treated with beta-blockers died in the initial 6 month treatment
period, compared with 22.6% of 3,647 patients not treated with beta-blockers died in the initial
6 month treatment period in 2006 and 9.6% of 14,041 beta-blocker users and 21.4% of 4,607
non-users died in 2007.5 Although this study had a large population size, the use of ICD-10
codes provided limited information on the severity of COPD and the adherence of the betablockers once the prescription was filled.
However, this benefit was mostly seen with cardioselective beta-blockers. In an Italian
population-based cohort study by Sessa et al., 51,124 COPD patients in total were treated for
heart failure, with 39,370 (76.9%) treated with cardioselective beta-blockers metoprolol,
bisoprolol, and nebivolol and 11,844 (23.1%) with the non-cardioselective beta-blocker
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carvedilol. Patients treated with carvedilol had a higher risk for heart failure hospitalization (HR
1.29, CI 1.18-1.40, p < 0.001), accounted for 26.8% of heart failure hospitalizations (95%CI
22.5-30.9%; p-value < 0.001), and were more likely to discontinue carvedilol due to
complications with 131 additional cases of beta-blocker discontinuation per 10,000 person-years
compared to patients using cardio-selective beta-blockers (p < 0.001).6 The study had a long
follow-up period of five years but relying on local health administration databases for
information regarding hospitalization made it possible some patients could have been
hospitalized outside the system and thus, not included in the data. The diagnoses for the betablocker prescriptions were not specified, allowing for asthma patients (who are known to have
more adverse effects to beta-blockers than COPD patients) to be included in the data.
The evidence from this study was corroborated by Huang et al. in their population-based
nested case control study of 16,067 case participants and 55,970 control participants. Patients
treated with noncardioselective beta-blockers such as labetalol and propranolol had an increased
risk of severe exacerbations (OR 1.49, CI 1.32-1.67 for labetalol, OR 1.16, 95% CI 1.10 – 1.23
for propranolol) compared with patients treated with selective beta-blockers such as betaxolol
(OR 0.75, 95% CI, 0.60 -.95).7 Furthermore, betaxolol had the lowest adjusted odds ratio (0.75)
compared with cardioselective beta-blockers metoprolol (0.88), bisoprolol (0.85), and atenolol
(0.97).7 Researchers were able to use generalized additive models (GAMs) to model the
duration and amount of beta-blockers patients were taking to accurately correlate the dosage of
beta-blockers with AECOPD.7 However, pulmonary function testing or quality of life
questionnaires were not examined to assess the severity of COPD.
In addition to evidence beta-blockers are the safer choice for the treatment of both AMI
and HF in COPD patients, beta-blockers were also found to be superior to non-dihydropyridine
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calcium channel blockers (NDCCB) in the treatment of AMI, which are often used as
alternatives to beta-blockers. When both were compared, patients treated with beta-blockers had
statistically significant overall lower mortality (HR 0.91, CI 0.83-0.99) compared with those
treated with NDCCB (HR 0.91, CI 0.83-0.99).8 Beta-blockers also decreased re-admissions due
to COPD exacerbations by 12-32% and these patients were less likely to use acute medical
services in one year for obstructive lung disease (HR 0.74, CI 0.69-0.80), which was statistically
significant.8 Although the study was limited as an observational study using data from an
insurance claims database, it is one of the first studies to compare beta-blockers with NDCCBs.
In a similar but smaller study by Zvizdic et al. 68 patients with moderate COPD, defined as
Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II, and severe COPD
(GOLD stage III), were treated with a combination of verapamil, a NDCCB, and digoxin or a
cardioselective beta-blocker. In patients with moderate and severe COPD, no statistically
significant differences were found in the number of acute exacerbations between the patients
treated with verapamil and digoxin versus cardioselective beta-blockers.9 In fact, patients in the
beta-blocker group had a decrease in the number of exacerbations in patients with moderate
COPD (0.600 compared with 1.333, p <0.007).9 This study not only compared cardioselective
beta-blockers with NDCCB but also examined the beta-blockers with varying degrees of COPD.
The principal concern for many providers prescribing beta-blockers is the potential
negative effect these drugs may have on pulmonary function in COPD patients. However,
evidence from many studies has indicated reduced pulmonary function is not associated with
beta-blocker use, especially cardioselective beta-blockers. In their cohort study of 5,162
patients, 557 of whom received beta-blockers, Maltais et al. used data from the multinational,
multicenter, randomized, double-blind TONADO study showing similar lung function, measured
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by FEV1, in moderate to severe patients treated with and without beta-blockers with a difference
of 0.010L (95% CI -0.009 – 0.028) in the FEV1 between the two groups. The patients were also
being treated with long-acting bronchodilators tiotropium and olodaterol. The quality of life
measured by St. George’s Respiratory Questionnaire (SGRQ) showed no statistically significant
difference between COPD patients being treated with beta-blockers compared with those who
were not being treated with beta-blockers.10 The concurrent use of long-acting bronchodilators
and beta-blockers was unique to this study and further quells fears providers have of interactions
between the two. Jabbal et al. also found in a small, randomized, open label cross-over study of
eighteen former smokers that patients treated specifically with bisoprolol, a cardioselective betablocker, had a statistically significant higher FEV1s and lung compliance, measured by area
under the reactance curve (AX), compared with carvedilol with no statistically significant
changes in these factors seen from baseline for the bisoprolol group.11 This difference was
especially true in patients treated with a long-acting beta2 agonist (LABA) and an inhaled
corticosteroids (ICS), further showing no interaction between LABAs and cardioselective betablockers.11 Although this trial was one of the few randomized studies performed, the small
sample size should be noted. Many of the authors also receive personal fees from
pharmaceutical companies such as Pfizer, AstraZeneca, and Boehringer Ingelheim. Dransfield et
al. also showed treatment of COPD patients with beta-blockers did not interfere with COPD
treatment regimens, including therapies with LABAs or ICSs. Using 5,159 participants with
baseline beta-blocker therapy from the Study to Understand Mortality and Morbidity in COPD
(SUMMIT), no statistically significant differences in FEV1 were seen at three, six, nine, or
twelve months; no increases in COPD exacerbations or increased risks of cardiovascular events
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were found.12 It is also important to note this study was also funded by the pharmaceutical
company GlaxoSmithKline.
In addition to the lack of harmful effects on COPD in patients with heart disease,
cardioselective beta-blockers may even reduce the amount and severity of COPD exacerbations.
In a prospective, multicenter observational cohort study, 3,464 participants of GOLD stage 2
through 4, former and current smokers, use of beta-blockers was associated with a statistically
significant reduction of total (IRR 0.73, 95% CI 0.60- 0.90) and severe exacerbations (IRR 0.67,
95% CI 0.49-0.93) with no increase in all-cause mortality.13 After adjusting for cardiovascular
disease such as CAD and CHF, patients using beta-blockers still had a decrease in total and
severe exacerbations and showed no change in the quality of life based on the SGRQ
questionnaire.13 Even in patients with severe COPD, beta-blocker use was associated with a
reduction in total (IRR 0.33, CI 0.19-0.58, P < 0.001) and severe COPD exacerbations (IRR
0.35, 95% CI 0.16 – 0.76, p < 0.05).13

Strengths/Limitations
Most studies had large sample sizes with diverse sampling from countries such as
Taiwan, Austria, and others across Europe. Patients also had short-term and long-term follow
up, which helped determine both the short-term and long-term consequences of treatment. The
studies available looked at the relationship of beta-blockers with COPD patients from various
angles, including the number of exacerbations and hospitalization for such exacerbations,
mortality, effects on pulmonary function, interactions with COPD therapies, and beta-blockers
compared to alternative pharmacotherapies. Some limitations included the retrospective and
observational nature of the studies, which cannot provide the same strength of evidence as
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prospective trials with randomization of a large and diverse sample of well-matched participants.
Many studies often did not specify if patients were treated with a cardioselective or a
nonselective beta-blocker, which is an important differentiation. Another limitation was the
source of data for many of these studies, which was indirect information collected from
insurance or billing agencies in the form of ICD codes, diagnostic tests ordered, and
prescriptions ordered and filled. Without direct patient data, errors may occur, such as generally
incorrect diagnoses or basing diagnoses or severity of COPD on prescriptions of inhalers, which
can be used both or COPD and asthma.
Randomized control studies targeting COPD patients with cardiovascular conditions such
as heart failure, arrhythmias, and myocardial infarctions need to be performed to strengthen the
currently available evidence. New research should examine endpoints of pulmonary function
tests, rate of exacerbations, and the long-term effects of beta-blockers on lung functioning.
Study design should specify whether beta-blockers were cardioselective or nonselective.
Information derived from further research would enhance clinicians’ ability to more effectively
manage their COPD patients with cardiovascular disease.

Conclusion
COPD is currently the fourth leading cause of death in the world and is slated to become
the 3rd leading cause of death in 2020.14 Cardiovascular disease is a common comorbidity in
COPD patients with mortality being higher from cardiac disease than respiratory disease in
patients with moderate COPD.14 Although clinicians are often hesitant to treat cardiovascular
disease with beta-blockers in COPD patients for fear of worsening pulmonary functioning and
exacerbating COPD, the evidence suggests otherwise. Beta-blockers, especially cardioselective
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beta-blockers have been shown to decrease mortality and increase survival rates especially when
treating myocardial infarctions and acute decompensating heart failure.4-7 These treatments do
not worsen pulmonary function and do not interact with other treatments for COPD, including
long-acting beta agonists.10-13 Beta-blockers have also been shown to produce superior outcomes
in treatment of cardiovascular disease in COPD patients compared with alternative therapies
such as non-dihydropyridine calcium channel blockers.8,9 The beneficial pharmacodynamic
effects of cardioselective beta-blockers are due to multiple changes in hemodynamics including
decreased oxygen demand, reduced sympathetic tone, modulation of chronic inflammation, and
increased production of nitric oxide in vascular smooth muscle reducing afterload. These
changes are thought to counteract the COPD burden, including arterial stiffness and systemic
inflammation, on the cardiovascular system.8
Overall, cardio-selective beta-blockers can be used cautiously in COPD patients to treat
cardiovascular disease, such as myocardial infarction, heart failure, arrhythmias, and coronary
artery disease. Providers can reasonably initiate this therapy but should continue to monitor
patients during treatment for any worsening of pulmonary function. More randomized control
trials with diverse and large patient samples with direct patient data are needed to strengthen the
evidence.

References
1

Lim KP, Loughrey S, Musk M, Lavender M, Wrobel J. Beta-blocker under-use in COPD
patients. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:3041-3046.
doi:10.2147/copd.s144333.
2

Malo de Molina R, Aguado S, Arellano C, Valle M, Ussetti P. Ischemic Heart Disease during
Acute Exacerbations of COPD. Med Sci (Basel). 2018;6(4):83. doi:10.3390/medsci6040083

9

Kubota Y, Tay WT, Asai K, et al. Chronic obstructive pulmonary disease and β-blocker
treatment in Asian patients with heart failure. ESC Heart Failure. 2017;5(2):297-305.
doi:10.1002/ehf2.12228.
3

4

Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic
obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a
nationwide observational study. Heart and Vessels. 2019;34(7):1158-1167. doi:10.1007/s00380019-01341-0.
Rezaei SS, Rinner C, Ratajczak P, Grossmann W, Gall W, Wolzt M. Use of beta‐blocker is
associated with lower mortality in patients with coronary artery disease with or without
COPD. Clin Respir J. 2018; 12: 2627– 2634. https://doi.org/10.1111/crj.12968
5

6

Sessa M, Mascolo A, Scavone C, et al. Comparison of Long-Term Clinical Implications of
Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With
Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Front
Pharmacol. 2018;9:1212. Published 2018 Oct 25. doi:10.3389/fphar.2018.01212
7

Huang YL, Lai C-C, Wang Y-H, et al. Impact of selective and nonselective beta-blockers on
the risk of severe exacerbations in patients with COPD. International Journal of Chronic
Obstructive Pulmonary Disease. 2017;Volume 12:2987-2996. doi:10.2147/copd.s145913.
Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. β-blockers after acute myocardial infarction in
patients with chronic obstructive pulmonary disease: A nationwide population-based
8

9

Zvizdic F, Begic E, Mujakovic A, et al. Beta-blocker Use in Moderate and Severe Chronic
Obstructive Pulmonary Disease. Medical Archives. 2019;73(2):72.
Maltais F, Buhl R, Koch A, et al. β-Blockers in COPD. Chest. 2018;153(6):1315-1325.
doi:10.1016/j.chest.2018.01.008.
10

11

Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth B. Cardiopulmonary
interactions with beta-blockers and inhaled therapy in COPD. QJM: An International Journal of
Medicine. 2017;110(12):785-792. doi:10.1093/qjmed/hcx155.
Dransfield MT, Mcallister DA, Anderson JA, et al. β-Blocker Therapy and Clinical Outcomes
in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened
Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic
Society. 2018;15(5):608-614. doi:10.1513/annalsats.201708-626oc.
12

Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD
exacerbations. Thorax. 2015;71(1):8-14. doi:10.1136/thoraxjnl-2015-207251
13

14

André S, Conde B, Fragoso E, Boléo-Tomé J, Areias V, Cardoso J. COPD and Cardiovascular
Disease. Pulmonology. 2019;25(3):168-176. doi:10.1016/j.pulmoe.2018.09.006
10

